Dahunos, Elvie D.
HRN: 12-49-73 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/24/2022
CO-AMOXICLAV 625MG (TAB)
07/24/2022
07/30/2022
ORAL
625mg
BID
S/P Repair Of 3rd Degree Perineal Laceration
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueReproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes